BioSpace News Archive

Curis, Inc. announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019.

United Urology Group has announced the consolidation of its Denver area group practices - Advanced Urology, Alpine Urology, and Foothills Urology – under a single brand, Colorado Urology.

Audentes Therapeutics, Inc. announced it has granted equity awards on April 3, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to sixteen individuals hired by Audentes from March 1 through April 1, 2019.

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of Salmonella infections involving six provinces: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec.

Reston Hospital Center (RHC) and Children’s National Health System in Washington, D.C. announced a strategic partnership to enhance the neonatology services at RHC.

Aerpio Pharmaceuticals, Inc. announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY.

Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York.

Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results demonstrating that RNA genetic testing (RGT), as a supplement to DNA genetic testing, improves variant classification in hereditary cancer genetic testing.

Realm Therapeutics plc announced that the Company received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the Company’s recent Assets Disposal, the Staff believes the Company is a “shell company” and, as such, the continued listing of American Depositary Shares representing the Company’s ordinary shares on Nasdaq is no longer warranted.

Exelixis, Inc. announced that Christopher J. Senner, the company’s Executive Vice President and Chief Financial Officer, and Andrew R. Peters, the company’s Vice President, Strategy, will provide an overview of the company at the 18th Annual Needham Healthcare Conference taking place on Wednesday, April 10, 2019 in New York, NY. The Exelixis presentation is scheduled that day for 4:10 PM EDT / 1:10 PM PDT.